Two Sigma Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Two Sigma Advisers’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,200	Closed	-$734K	–	2640
2023 Q2	$734K	Sell	7,200 -28,000	-80%	-$2.65M	﹤0.01%	1663
2023 Q1	$3.2M	Sell	35,200 -15,000	-30%	-$880K	0.01%	1020
2022 Q4	$1.91M	Buy	50,200 +25,200	+101%	+$867K	0.01%	1271
2022 Q3	$628K	Buy	+25,000	New	+$693K	﹤0.01%	1746
2020 Q4	–	Sell	-51,989	Closed	-$5.07M	–	2648
2020 Q3	$5.07M	Sell	51,989 -9,100	-15%	-$1.14M	0.01%	762
2020 Q2	$9.53M	Buy	61,089 +54,800	+871%	+$8.33M	0.03%	572
2020 Q1	$908K	Buy	+6,289	New	+$1.21M	﹤0.01%	1540
2019 Q2	–	Sell	-3,156	Closed	-$270K	–	2482
2019 Q1	$270K	Buy	+3,156	New	+$262K	﹤0.01%	2020

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Two Sigma Advisers's RETA Position: Q3 2023 in Review

Two Sigma Advisers sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 7,200 shares — an estimated $734K sold.

Two Sigma Advisers first reported a position in RETA in Q1 2019 and held it in 8 quarters. The position peaked at $9.53M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Two Sigma Advisers reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Two Sigma Advisers sold 7,200 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $734K.
Two Sigma Advisers first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 8 quarters.
Two Sigma Advisers's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.53M in Q2 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.